Formulations of dietary supplements and herbal extracts for relaxation and anxiolytic action: Relarian™

Medical Science Monitor

Volumn 15, Issue 11, 2009, Pages

  Weeks, Benjamin S ^a  

^a ADELPHI UNIVERSITY   (United States)

Author keywords

5 HTP; Anxiolytic; Dietary supplement; GABA; Theanine; Valerian

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 4 HYDROXYBUTYRIC ACID; 5 HYDROXYTRYPTOPHAN; ALPRAZOLAM; ANGELICA SINENSIS EXTRACT; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; FLAVONOID; GABAPENTIN; GOOD NIGHT; HYPERFORIN; KAVA; KAVA EXTRACT; MAGNOLIA EXTRACT; MORINDA CITRIFOLIA EXTRACT; MUSCIMOL; NORADRENALIN; PHELLONDENDRON EXTRACT; PLANT EXTRACT; POTASSIUM CHANNEL; PROLOFTIN; RELARIAN; RELORA; SEDITOL; SEROTONIN; SODIUM CHANNEL; STEROID; THEANINE; TRYPTOPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLPIDEM TARTRATE;

ALCOHOLISM; ANXIETY; ANXIETY DISORDER; DEPRESSION; DIET SUPPLEMENTATION; DRUG DEPENDENCE; DRUG FORMULATION; HUMAN; HUMULUS LUPULUS; HYPERICUM PERFORATUM; HYSTERIA; INSOMNIA; MAGNOLIACEAE; MEDICINAL PLANT; MELISSA OFFICINALIS; MOOD; MOOD DISORDER; MUSCLE RELAXATION; MUSCLE TONE; NONHUMAN; NORADRENALIN UPTAKE; PAIN; PANIC; PASSION FRUIT; PHELLONDENDRON; PLANT ROOT; REVIEW; SCHIZOPHRENIA; SCUTELLARIA; SEDATION; SKELETAL MUSCLE; STRESS MANAGEMENT; TRANQUILIZING ACTIVITY; VALERIANA OFFICINALIS;

5-HYDROXYTRYPTOPHAN; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; DIETARY SUPPLEMENTS; DRUG COMBINATIONS; DRUG COMPOUNDING; GAMMA-AMINOBUTYRIC ACID; GLUTAMATES; HUMANS; PLANT EXTRACTS; RELAXATION;

EID: 71649108028     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Farnworth ER: The evidence to support health claims for probiotics. J Nutr, 2008; 138(6): 1250S-54S
2. Zulet MA, Marti A, Parra MD, Martínez JA: LinksInflammation and conjugated linoleic acid: mechanisms of action and implications for human health. J Physiol Biochem, 2005; 61(3): 483-494 (Pubitemid 43091766)
3. Dulak J: LinksNutraceuticals as anti-angiogenic agents: hopes and reality. J Physiol Pharmacol, 2005; 56(Suppl.1): 51-67 (Pubitemid 44922295)
4. Riccioni G, Mancini B, Di Ilio E et al: Protective effect of lycopene in cardiovascular disease. Eur Rev Med Pharmacol Sci, 2008; 12(3): 183-190
5. Ji HF, Zhang HY: Multipotent natural agents to combat Alzheimer's disease. Functional spectrum and structural features. Acta Pharmacol Sin, 2008; 29(2): 143-151
6. Plourde M, Cunnane SC: Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. Appl Physiol Nutr Metab, 2007; 32(4): 619-634
7. Janssens W, Lehouck A, Carremans C et al: Vitamin D beyond bones in chronic obstructive pulmonary disease: time to act. Am J Respir Crit Care Med, 2009; 179(8): 630-636
8. Weinreb O, Mandel S, Amit T, Youdim MB: Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutr Biochem, 2004; 15(9): 506-516 (Pubitemid 39209392)
9. Joseph JA, Shukitt-Hale B, Willis LM: LinksGrape juice, berries, and walnuts affect brain aging and behavior. J Nutr, 2009; 139(9): 1813S-17S
10. Kuroda M, Nozawa Y: Effect of dried-bonito broth on mood states: a pooled analysis of four randomized controlled human trials. Biomed Res, 2008; 29(4): 175-179
11. Stahl LA, Begg DP, Weisinger RS, Sinclair AJ: The role of omega-3 fatty acids in mood disorders. Curr Opin Investig Drugs, 2008; 9(1): 57-64
12. McDougall GJ Jr, Austin-Wells V, Zimmerman T: Utility of nutraceutical products marketed for cognitive and memory enhancement. J Holist Nurs, 2005; 23(4): 415-433
13. Willis LM, Shukitt-Hale B, Joseph JA: Recent advances in berry supplementation and age-related cognitive decline. Curr Opin Clin Nutr Metab Care, 2009; 12(1): 91-94
14. Saletu B, Anderer P, Di Padova C et al: Electrophysiological neuroimaging of the central effects of S-adenosyl-L-methionine by mapping of electroencephalograms and event-related potentials and low-resolution brain electromagnetic tomography. Am J Clin Nutr, 2002; 76(5): 1162S-71S (Pubitemid 35244696)
15. Cauffield JS, Forbes HJ: Dietary supplements used in the treatment of depression, anxiety, and sleep disorders. Lippincotts Prim Care Pract, 1999; 3(3): 290-304
16. Turner EH, Blackwell AD: 5-Hydroxytryptophan plus SSRIs for interferon- induced depression: synergistic mechanisms for normalizing synaptic serotonin. Med Hypotheses, 2005; 65(1): 138-144
17. Deng S, West BJ, Palu AK et al: Noni as an anxiolytic and sedative: a mechanism involving its gamma-aminobutyric acidergic effects. Phytomedicine, 2007; 14(7-8): 517-522 (Pubitemid 47071884)
18. Kennedy DO, Little W, Haskell CF, Scholey AB: Anxiolytic effects of a combination of Melissa officinalis and Valeriana officinalis during laboratory induced stress. Phytother Res, 2006; 20(2): 96-102 (Pubitemid 43266832)
19. Abdou AM, Higashiguchi S, Horie K et al: Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans. Biofactors, 2006; 26(3): 201-208 (Pubitemid 44359508)
20. Krystal AD: Treating the health, quality of life, and functional impairments in insomnia. J. Clin Sleep Med, 2007; 3(1): 63-72
21. Leathwood PD, Chauffard F, Heck E, Munoz-Box R: Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav, 1982; 17: 65-71
22. Balderer G, Borbely AA: Effect of valerian on human sleep. Psychopharmacology [Berl], 1985; 87: 406-409
23. Koetter U, Schrader E, Käufeler R, Brattström A: A randomized, double blind, placebo-controlled, prospective clinical study to demonstrate clinical efficacy of a fixed valerian hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorder. Phytother Res, 2007; 21(9): 847-851 (Pubitemid 47401854)
24. Dimpfel W, Suter A: Sleep improving effects of a single dose administration of a valerian/hops fluid extract - a double blind, randomized, placebo-controlled sleep-EEG study in a parallel design using electrohypnograms. Eur J Med Res, 2008; 13(5): 200-204
25. Kohnen R, Oswald WD: The effects of valerian, propranolol, and their combination on activation, performance, and mood of healthy volunteers under social stress conditions. Pharmacopsychiatry, 1988; 21: 447-448 (Pubitemid 19024221)
26. Lindahl O, Lindwall L: Double blind study of a valerian preparation. Pharmacol Biochem Behav, 1989; 32: 1065-1066 (Pubitemid 19210300)
27. Wheatley D: Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability. J Psychopharmacol, 2005; 19: 414-421
28. Herrera-Arellano A, Luna-Villegas G, Cuevas-Uriostegui ML et al: Polysomnographic evaluation of the hypnotic effect of Valeriana edulis standardized extract in patients suffering from insomnia. J Planta Med, 2001; 67(8): 695-699 (Pubitemid 33044472)
29. Andreatini R, Sartori VA, Seabra ML, Leite JR: sEffect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo- controlled pilot study. Phytother Res, 2002; 16(7): 650-654 (Pubitemid 35334186)
30. Müller SF, Klement S: A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children. Phytomedicine, 2006; 13(6): 383-387 (Pubitemid 43744416)
31. Bhattacharyya D, Jana U, Debnath PK, Sur TK: Initial exploratory observational pharmacology of Valeriana wallichii on stress management: a clinical report. Nepal Med Coll J, 2007; 9(1): 36-39
32. Kennedy DO, Little W, Haskell CF, Scholey AB: Anxiolytic effects of a combination of Melissa officinalis and Valeriana officinalis during laboratory induced stress. Phytother Res, 2006; 20(2): 96-102 (Pubitemid 43266832)
33. Sarris J, Kavanagh DJ, Byrne G et al: The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl), 2009; 205(3): 399-407
34. Teschke R, Schwarzenboeck A, Hennermann KH: Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol, 2008; 20(12): 1182-1193
35. Gounder R: Kava consumption and its health effects. Pac Health Dialog, 2006; 13(2): 131-135
36. Wolfson P, Hoffmann DL: An investigation into the efficacy of Scutellaria lateriflora in healthy volunteers. Altern Ther Health Med, 2003; 9(2): 74-78 (Pubitemid 36286409)
37. Dimpfel W, Pischel I, Lehnfeld R: Effects of lozenge containing lavender oil, extracts from hops, lemon balm and oat on electrical brain activity of volunteers. Eur J Med Res, 2004; 9(9): 423-431
38. Kennedy DO, Little W, Scholey AB: Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (Lemon Balm). Psychosom Med, 2004; 66(4): 607-613
39. Lu K, Gray MA, Oliver C et al: The acute effects of L-theanine in comparison with alprazolam on anticipatory anxiety in humans. Hum Psychopharmacol, 2004; 19(7): 457-465 (Pubitemid 39378268)
40. Gomez-Ramirez M, Kelly SP, Montesi JL, Foxe JJ: The effects of L-theanine on alpha-band oscillatory brain activity during a visuo-spatial attention task. Brain Topogr, 2009; 22(1): 44-51
41. Gomez-Ramirez M, Higgins BA, Rycroft JA et al: The deployment of intersensory selective attention: a high-density electrical mapping study of the effects of theanine. Clin Neuropharmacol. 2007; 30(1): 25-38 (Pubitemid 46204315)
42. Kelly SP, Gomez-Ramirez M, Montesi JL, Foxe JJ: L-theanine and caffeine in combination affect human cognition as evidenced by oscillatory alpha-band activity and attention task performance. J Nutr, 2008; 138(8): 1572S-77S
43. Trachte GJ, Uncini T, Hinz M: Both stimulatory and inhibitory effects of dietary 5-hydroxytryptophan and tyrosine are found on urinary excretion of serotonin and dopamine in a large human population. Neuropsychiatr Dis Treat, 2009; 5: 227-235
44. Croonenberghs J, Verkerk R, Scharpe S et al: Serotonergic disturbances in autistic disorder: L-5-hydroxytryptophan administration to autistic youngsters increases the blood concentrations of serotonin in patients but not in controls. Life Sci, 2005; 76(19): 2171-2183 (Pubitemid 40283642)
45. Ruhe HG, Mason NS, Schene AH: Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry, 2007; 12: 331-359
46. Rot M, Mathew SJ, Charney DS: LinksNeurobiological mechanisms in major depressive disorder. CMAJ, 2009; 180(3): 305-313
47. Young SN: How to increase serotonin in the human brain without drugs. J Psychiatry Neurosci, 2007; 32(6): 394-399
48. Young SN, Leyton M: The role of serotonin in human mood and social interaction. Insight from altered tryptophan levels. Pharmacol Biochem Behav, 2002; 71(4): 857-865
49. Randløv C, Mehlsen J, Thomsen CF et al: The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia - a double-blind placebo-controlled study. Phytomedicine, 2006; 13(4): 215-221
50. Movafegh A, Alizadeh R, Hajimohamadi F et al: Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study. Anesth Analg, 2008; 106(6): 1728-1732
51. Kalman DS, Feldman S, Feldman R et al: Effect of a proprietary Magnolia and Phellodendron extract on stress levels in healthy women: a pilot, double-blind, placebo-controlled clinical trial. Nutr J, 2008; 7: 11 (Pubitemid 351641957)
52. Nemeroff CB: The role of GABA in thepathophysiology and treatment of anxiety disorders. Psychopharmacol Bull, 2003; 37: 133-146
53. Kendell SF, Krystal JH, Sanacora G: GABA andglutamate systems as therapeutic targets in depressionand mood disorders. Expert Opin Ther Targets, 2005; 9: 153-168
54. Kugaya A, Sanacora G: Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr, 2005; 10: 808-819 (Pubitemid 41531934)
55. Krystal JH, Sanacora G, Blumberg H: Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry, 2002; 7: S71-80 (Pubitemid 34280651)
56. Treiman DM: GABAergic mechanisms in epilepsy. Epilepsia, 2001; 42: 8-12
57. Gottesmann C: GABA mechanisms and sleep. Neuroscience, 2002; 111: 231-239
58. Chen Z, Yang J, Tobak A: Designing new treatments for depression and anxiety. IDrugs, 2008; 11(3): 189-197 (Pubitemid 351323373)
59. Shiah IS, Yatham LN: GABA function in mooddisorders: an update and critical review. Life Sci, 1998; 63: 1289-1303 (Pubitemid 29369125)
60. Green ML, Green RG, Santoro W: Daily relaxationmodifies serum and salivary immunoglobulins andpsychophysiologic symptom severity. Biofeedback SelfRegul, 1988; 13: 187-199
61. Bazil CW, Battista J, Basner RC: Gabapentinimproves sleep in the presence of alcohol. J Clin SleepMed, 2005; 1: 284-287
62. Abdou AM, Higashiguchi S, Horie K et al: Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans. Biofactors, 2006; 26(3): 201-208 (Pubitemid 44359508)
63. Thorne Research, Inc: Gamma-Aminobutyric Acid (GABA). Alternative Medicine Review, 2007; 12(3)
64. Jorgensen EM: GABA WormBook. 2005; 1-13. Links
65. Jacob TC, Moss SJ, Jurd R: GABA(A) receptor trafficking and its role in the dynamic modulation of neuronal inhibition. Nat Rev Neurosci, 2008; 9(5): 331-343
66. Markwardt S, Overstreet-Wadiche L: GABAergic signalling to adult-generated neurons. J Physiol, 2008; 586(16): 3745-3749
67. Spila B, Szumiłło A: [Gabapentin (GBP) in panic disorders - case report] Psychiatr Pol, 2006; 40(6): 1061-1068 (Pubitemid 46225066)
68. Ashcroft FM, Kakei M, Kelly RP: Rubidium and sodium permeability of the ATP-sensitive K+ channel in single rat pancreatic beta-cells. J Physiol, 1989; 408: 413-429 (Pubitemid 19040029)
69. Deng S, West BJ, Palu AK et al: Noni as an anxiolytic and sedative: a mechanism involving its gamma-aminobutyric acidergic effects. Phytomedicine, 2007; 14(7-8): 517-522 (Pubitemid 47071884)
70. Deng S, Chen SN, Lu J et al: GABAergic phthalide dimers from Angelica sinensis (Oliv.) Diels. Phytochem Anal, 2006; 17(6): 398-405 (Pubitemid 44697747)
71. Huen MS, Hui KM, Leung JW et al: Naturally occurring 2′-hydroxyl- substituted flavonoids as high-affinity benzodiazepine site ligands. Biochem Pharmacol, 2003; 66(12): 2397-2407
72. Yuan CS, Dey L, Wang A et al: Kavalactones and dihydrokavain modulate GABAergic activity in a rat gastric-brainstem preparation. Planta Med, 2002; 68(12): 1092-1096 (Pubitemid 36140314)
73. J Ma Y, Ma H, Eun JS et al: Methanol extract of Longanae Arillus augments pentobarbital-induced sleep behaviors through the modification of GABAergic systems. Ethnopharmacol, 2009; 122(2): 245-250
74. Chatterjee SS, Biber A, Weibezahn C: Stimulation of glutamate, aspartate and gamma-aminobutyric acid release from synaptosomes by hyperforin. Pharmacopsychiatry, 2001; 34(Suppl.1): S11-19 (Pubitemid 32701733)
75. Di Carlo G, Borrelli F, Ernst E, Izzo AA: Trends Pharmacol Sci, 2001; 22(11): 557-559
76. Awad R, Levac D, Cybulska P et al: Effects of traditionally used anxiolytic botanicals on enzymes of the gamma-aminobutyric acid (GABA) system. Can J Physiol Pharmacol, 2007; 85(9): 933-942 (Pubitemid 350189736)
77. Yuan CS, Mehendale S, Xiao Y et al: The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Analg, 2004; 98(2): 353-358 (Pubitemid 38129379)
78. Khom S, Baburin I, Timin E et al: Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificity. Neuropharmacology, 2007; 53(1): 178-187 (Pubitemid 47125958)
79. Trauner G, Khom S, Baburin I et al: Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acid. Planta Med, 2008; 74(1): 19-24 (Pubitemid 351251378)
80. Benke D, Barberis A, Kopp S et al: GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology. 2009; 56(1): 174-181
81. Ortiz JG, Nieves-Natal J, Chavez P: Effects of Valeriana officinalis extracts on [3H]flunitrazepam binding, synaptosomal [3H]GABA uptake, and hippocampal [3H]GABA release. Neurochem Res, 1999; 24(11): 1373-1378 (Pubitemid 129723674)
82. Malva JO, Santos S, Macedo T: Neuroprotective properties of Valeriana officinalis extracts. Neurotox Res, 2004; 6(2): 131-140
83. Grundmann O, Nakajima J, Seo S, Butterweck V: Epub 2006 Oct 13. Anti-anxiety effects of Apocynum venetum L. in the elevated plus maze test. J Ethnopharmacol, 2007; 110(3): 406-411
84. Jung JW, Yoon BH, Oh HR et al: Anxiolytic-like effects of Gastrodia elata and its phenolic constituents in mice. Biol Pharm Bull, 2006; 29(2): 261-265
85. Yu HS, Lee SY, Jang CG: Involvement of 5-HT1A and GABAA receptors in the anxiolytic-like effects of Cinnamomum cassia in mice. Pharmacol Biochem Behav, 2007; 87(1): 164-170
86. Grundmann O, Wang J, McGregor GP, Butterweck V: Anxiolytic activity of a phytochemically characterized Passiflora incarnata extract is mediated via the GABAergic system. Planta Med, 2008; 74(15): 1769-1773
87. Hadjikhani R: Anxiolytic-like Effects of Dichloromethane Extracts of Valerian (DEV) in Adult Male Wistar Rats. World Academy of Science, Engineering and Technology, 2009; (55): 532-536
88. Hattesohl M, Feistel B, Sievers H et al: Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties. Phytomedicine, 2008; 15(1-2): 2-15 (Pubitemid 50021760)
89. Andreatini R, Sartori VA, Seabra ML, Leite JR: Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo- controlled pilot study. Phytother Res, 2002; 16(7): 650-654 (Pubitemid 35334186)
90. Ziegler G, Ploch M, Miettinen-Baumann A, Collet W: Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia - a randomized, double-blind, comparative clinical study. Eur J Med Res, 2002; 7(11): 480-486
91. Cuellar NGand Ratcliffe SJ: Does valerian improve sleepiness and symptom severity in people with restless legs syndrome? Altern Ther Health Med, 2009; 15(2): 22-28
92. Nobre AC, Rao A, Owen GN: L-theanine, a natural constituent in tea, and its effect on mental state. Asia Pac J Clin Nutr, 2008; 17(Suppl.1): 167-168
93. Kimura K, Ozeki M, Juneja LR, Ohira H: L-Theanine reduces psychological and physiological stress responses. Biol Psychol, 2007; 74(1): 39-45 (Pubitemid 44781395)
94. Lu K, Gray MA, Oliver C et al: The acute effects of L-theanine in comparison with alprazolam on anticipatory anxiety in humans. Hum Psychopharmacol, 2004; 19(7): 457-465 (Pubitemid 39378268)
95. Nathan PJ, Lu K, Gray M, Oliver C: The neuropharmacology of L-theanine(N-ethyl-L-glutamine): a possible neuroprotective and cognitive enhancing agent. J Herb Pharmacother, 2006; 6(2): 21-30 (Pubitemid 44964090)
96. Yamada T, Terashima T, Kawano S et al: Theanine, gamma- glutamylethylamide, a unique amino acid in tea leaves, modulates neurotransmitter concentrations in the brain striatum interstitium in conscious rats. Amino Acids, 2009; 36(1): 21-27
97. Yamada T, Terashima T, Honma H et al: Effects of theanine, a unique amino acid in tea leaves, on memory in a rat behavioral test. Biosci Biotechnol Biochem, 2008; 72(5): 1356-1359 (Pubitemid 351877008)
98. Egashira N, Ishigami N, Pu F et al: Theanine prevents memory impairment induced by repeated cerebral ischemia in rats. Phytother Res, 2008; 22(1): 65-68 (Pubitemid 351155914)
99. Egashira N, Hayakawa K, Mishima K et al: Neuroprotective effect of gamma-glutamylethylamide (theanine) on cerebral infarction in mice. Neurosci Lett, 2004; 363(1): 58-61 (Pubitemid 38639851)
100. Egashira N, Hayakawa K, Osajima M et al: Involvement of GABA(A) receptors in the neuroprotective effect of theanine on focal cerebral ischemia in mice. J Pharmacol Sci, 2007; 105(2): 211-214 (Pubitemid 350106812)
101. Berger M, Gray JA, Roth BL: The expanded biology of serotonin. Annual Review of Medicine, 2009; 60: 355-366
102. Holmes A, Yang RJ, Murphy DL, Crawley JN: Evaluation of antidepressant- related behavioral responses in mice lacking the serotonin transporter. Neuropsychopharmacology, 2002; 27(6): 914-923 (Pubitemid 35447628)
103. Jennings KA, Loder MK, Sheward WJ et al: Increased expression of the 5-HT transporter confers a low-anxiety phenotype linked to decreased 5-HT transmission. J Neurosci, 2006; 26(35): 8955-8964
104. Hashimoto S: Anxiolytic effects of serotonin reuptake inhibitors and their mechanism of action. Hokkaido Igaku Zasshi, 2000; 75(6): 421-436
105. Yamauchi M, Hiraoka S, Imanishi T: Role of the serotonergic nervous system in anxiety disorders and the anxiolytic mechanism of selective serotonin reuptake inhibitors. Nihon Shinkei Seishin Yakurigaku Zasshi, 2006; 26(5-6): 193-198 (Pubitemid 46063758)
106. Członkowska AI, Zienowicz M, Bidziński A et al: The role of neurosteroids in the anxiolytic,antidepressive- and anticonvulsive effects of selective serotonin reuptake inhibitors. Med Sci Monit, 2003; 9(11): RA270-75
107. Birdsall TC: 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev, 1998; 3(4): 271-280
108. Grimmett A, Sillence MN: Calmatives for the excitable horse: a review of L-tryptophan. Vet J, 2005; 170(1): 24-32 (Pubitemid 40916332)
109. Mizoguchi K, Tanaka Y, Tabira T: Anxiolytic effect of a herbal medicine, yokukansan, in aged rats: involvement of serotonergic and dopaminergic transmissions in the prefrontal cortex. J Ethnopharmacol, 2009 Sep 29
110. Egashira N, Iwasaki K, Ishibashi A et al: Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry, 2008; 32(6): 1516-1520
111. Yi LT, Xu Q, Li YC et al: Antidepressant-like synergism of extracts from magnolia bark and ginger rhizome alone and in combination in mice. Prog Neuropsychopharmacol Biol Psychiatry, 2009; 33(4): 616-624
112. Qin YJ, Zeng YS, Zhou CC et al: Effects of Rhodiola rosea on level of 5-hydroxytryptamine, cell proliferation and differentiation, and number of neuron in cerebral hippocampus of rats with depression induced by chronic mild stress. Zhongguo Zhong Yao Za Zhi, 2008; 33(23): 2842-2846
113. Bystritsky A, Kerwin L, Feusner JD: A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). J Altern Complement Med, 2008; 14(2): 175-180
114. An L, Zhang YZ, Yu NJ et al: Role for serotonin in the antidepressantlike effect of a flavonoid extract of Xiaobuxin-Tang. Pharmacol Biochem Behav, 2008; 89(4): 572-580
115. Murphy SE, Longhitano C, Ayres RE et al: The role of serotonin in nonnormative risky choice: the effects of tryptophan supplements on the "reflection effect" in healthy adult volunteers. J Cogn Neurosci, 2009; 21(9): 1709-1719
116. Williams E, Stewart-Knox B, Bradbury I et al: Effect of folic acid supplementation on mood and serotonin response in healthy males. Br J Nutr, 2005; 94(4): 602-608 (Pubitemid 41555503)
117. Powell SL, Gödecke T, Nikolic D et al: In vitro serotonergic activity of black cohosh and identification of N(omega)-methylserotonin as a potential active constituent. J Agric Food Chem, 2008; 56(24): 11718-11726
118. Deng S, Chen SN, Yao P et al: Serotonergic activity-guided phytochemical investigation of the roots of Angelica sinensis. J Nat Prod, 2006; 69(4): 536-541 (Pubitemid 43798097)
119. Tadros MG, Mohamed MR, Youssef AM et al: Involvement of serotoninergic 5-HT1A/2A, alpha-adrenergic and dopaminergic D1 receptors in St. John's wort-induced prepulse inhibition deficit: a possible role of hyperforin. Behav Brain Res, 2009; 199(2): 334-339
120. Chase JE, Gidal BE: Melatonin: therapeutic use in sleep disorders. Ann Pharmacother, 1997; 31(10): 1218-1226